Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Spyre Therapeutics, Inc. Banner

Spyre Therapeutics, Inc.

SYRE Stock Analysis

Page title

Section title

About Spyre Therapeutics, Inc.

Biotechnology
Healthcare

Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Spyre Therapeutics, Inc. Key Metrics

Market Cap
$2B
52 Weeks Low
$8.43
52 Weeks High
$47.97
P/B
3.63x
P/E
-7.30x
P/S
1.47Kx

Upcoming Events

    SYRE Analyst Forecasts

    ‌
    ‌

    SYRE Financials

    SYRE Income Statement Key Metrics

    • Revenue(TTM)1.04 M
    • Gross Profit(TTM)78,000
    • EBITDA(TTM)-164.31 M
    • Net Income(TTM)-185.98 M
    • EPS Diluted(TTM)-15.45

    Decode SYRE's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    SYRE earnings and revenue history

    SYRE Return on Equity

    See how efficiently SYRE generates profit for it's shareholders.

    0%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity Growth

    SYRE's Return on Equity has grown significantly over the past 10 years, increasing by over 23.30%.

    SYRE Revenue Growth

    See how SYRE has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    SYRE's revenue has shown poor growth over the past 10 years, increasing by only -18.67%.